Panobacumab (KBPA101) (1-4 mg/kg; i.v.; once) protects mice from systemic infection with P. aeruginosa serotype O11 in a murine burn wound model[1].
Panobacumab (KBPA101) (0.005-0.4 mg/kg; i.v.; once) protects mice from local lung infection with P. aeruginosa serotype O11 in an acute lung infection model[1].
| Animal Model: | Female NMRI mice, murine burn wound model[1] |
| Dosage: | 1, 2, or 4 mg/kg |
| Administration: | Intravenous injection, single dose |
| Result: | Significantly reduced mortality compared to untreated control animals administered either immediately or 4 h postchallenge. |
| Animal Model: | BALB/c mice, acute lung infection model[1] |
| Dosage: | 0.005 to 0.4 mg/kg |
| Administration: | Intravenous injection, single dose |
| Result: | Led to rapid clearance of P. aeruginosa from the lung, completely cleared systemic P. aeruginosa from the spleen, whereas live bacteria were still present in untreated mice at 48 h postchallenge, showed milder macroscopic lung pathology at 6 and 24 h after infection. |
